Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Experts Video Reports: Lung Cancer track

Learn about key results illustrated by slides from the sessions!

Lung Cancer track 2022.
The selection of study results covered in this track is exclusively under the responsibility of ESMO and the speakers selected by ESMO.

Expert Video Report on featured outcomes from novel NSCLC trials - AACR 2022

Reporting onsite from AACR 2022 in New Orleans, Nicolas Girard discusses practice changing results from the CheckMate 816 trial involving the addition of neoadjuvant nivolumab to chemotherapy for resectable (IB-IIIA) NSCLC. He further reviews the encouraging results at 2 years from CodeBreaK100 with sotorasib in pretreated patients with KRASp.G12C-mutated NSCLC.

ESMO 2021 Expert Video Report on novelties in metastatic NSCLC

Reporting from the ESMO Congress 2021, Robin Cornelissen discusses novel precision medicine strategies for patients with NSCLC. He explains the response results from the ZENITH20-4 cohort in first-line treatment with poziotinib for HER2 exon 20 mutated NSCLC and reviews promising results from the Atalante-1 phase III study, testing a vaccine strategy in patients with HLA-A2+ NSCLC after immunotherapy failure. Finally, he explains the outcomes from datopotamab deruxtecan in mNSCLC with actionable genomic alterations by detailing the encouraging results from the TROPION-PanTumor01 study.

Expert Video Report on therapeutic advances in NSCLC from 2021 ASCO Annual Meeting

Reporting from 2021 ASCO Annual Meeting, Heather Wakelee comments on promising results from IMPOWER 010 testing atezolizumab vs best standard of care after adjuvant chemotherapy for stage II NSCLC with tumour expressing PD-L1. She also reports the overall survival results and subgroup analysis from the CodeBreaK 100 trial evaluating sotorasib in pretreated KRAS G12C mutated NSCLC, as the drug has just been approved in the US.

#ESMO20 Expert Video Report on long term ICI outcomes in lung cancer

Reporting from ESMO Virtual Congress 2020, Noemi Reguart comments on long term follow-up results from studies testing first-line and maintenance immunotherapy in advanced NSCLC. She also discusses promising results testing a combination of ICI with chemotherapy in extensive stage SCLC, and emphasises the need for more exploration to identify which groups of patient may benefit the most.

Expert video report on lung cancer from ASCO 2020

Reporting remotely on findings presented at ASCO 2020 Virtual Meeting, Egbert Smit comments on important and potentially practice changing study results in NSCLC.

ESMO 2019 Expert Video Report on Small Cell Lung Cancer

Reporting from ESMO 2019 Congress, Martin Reck comments on the results from 2 trials studying a combination of chemotherapy and immune checkpoint inhibitor in the first-line treatment of patients with extensive stage small cell lung cancer (SCLC), and a trial studying anlotinib in heavily pretreated patients with relapsed SCLC. He explains that after decades of research there are moderately positive results and more analysis is needed to identify meaningful biomarkers.

ESMO 2019 Expert Video Report on Malignant Pleural Mesothelioma

Reporting from ESMO Congress 2019, Sanjay Popat comments on results from 3 studies presented in Malignant Pleural Mesothelioma. Considering the results, he thinks that we need to better identify the patients who may benefit from checkpoint inhibitors. In the relapse setting we have modest activity of 22% overall response rate, and to improve those results we should look at checkpoint inhibitors in the front line setting.

ESMO Expert video reports on state of art of Tumour Mutational Burden in NSCLC

Reporting from ELCC 2019 in Geneva, M. Pérol explains the Tumour Mutational Burden from the biomarker’s perspective, details recent assessment methods and how the test results may be useful in Non-Small Cell Lung Cancer patients to select first-line treatment.

ESMO Expert video report on CTC and ctDNA in advanced NSCLC

Reporting from ELCC 2019 in Geneva, C. Lindsay comments on the results of a multicentre study which aimed to analyse circulating tumour cells in advanced NSCLC and their potential clinical role. He also showed results from a study analysing plasma ctDNA in advanced NSCLC patients with isolated CNS metastases.

ESMO Expert Video Report on NSCLC

Reporting from AACR 2019 in Atlanta, M. Garassino comments on two studies about the immunotherapy outcomes in NSCLC patients presenting with brain or liver metastasis, and the use of Tumour Mutational Burden as a biomarker in metastatic NSCLC patients.

More ESMO videos on Thoracic Tumours from the ESMO Channel

View the full playlist on the ESMO Channel

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.